만성 B형간염 환자에서 adefovir dipivoxil 투여에 의해 발생한 심한 저인산염혈증 1예
A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Adefovir dipivoxyl (ADV) effectively suppresses hepatitis B virus (HBV) replication but exhibits nephrotoxicity with severe hypophosphatemia when administered at a high dosage. This is the first report of severe hypophosphatemic osteomalacia induced by ADV at 10 mg/day. A 42-year-old man with HBV-related chronic liver disease presented with generalized bone pain, especially in the left ankle. He had been taking ADV for more than 1.5 years following a clinical breakthrough due to lamivudine-resistant HBV. Aggravating severe hypophosphatemia and elevated serum alkaline phosphatase levels with high bone fraction had been noted after 6 months of ADV therapy. Bone densitometry, simple bone X-rays, and a whole-body bone scan demonstrated osteoporosis and multiple areas with hot uptake, especially in the left ankle. All the image findings and symptoms improved after correcting the hypophosphatemia.
Abstract
Adefovir dipivoxyl (ADV) effectively suppresses hepatitis B virus (HBV) replication but exhibits nephrotoxicity with severe hypophosphatemia when administered at a high dosage. This is the first report of severe hypophosphatemic osteomalacia induced by ADV at 10 mg/day. A 42-year-old man with HBV-related chronic liver disease presented with generalized bone pain, especially in the left ankle. He had been taking ADV for more than 1.5 years following a clinical breakthrough due to lamivudine-resistant HBV. Aggravating severe hypophosphatemia and elevated serum alkaline phosphatase levels with high bone fraction had been noted after 6 months of ADV therapy. Bone densitometry, simple bone X-rays, and a whole-body bone scan demonstrated osteoporosis and multiple areas with hot uptake, especially in the left ankle. All the image findings and symptoms improved after correcting the hypophosphatemia.
참고문헌 (10)
- Kramata P, "Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerase alpha, delta and epsilon", Mol Pharmacol, 49, pp.1005~1011 (1996)
- Kahn J, "Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized, controlled trial", JAMA, 282, pp.2305~2312 (1999)
- Izzedine H, "Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies", Kidney Int, 66, pp.1153~1158 (2004)
- Lee HC, "A case of adult onset hypophosphatemic osteomalacia", J Korean Soc Endocrinol, 6, pp.75~81 (1991)
- Tanji N, "Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion", Hum Pathol, 32, pp.734~740 (2001)
- Bringhurst FR, "Bone and mineral metabolism in health and disease", pp.2241~2243 (2005), McGraw-Hill
- Wilson DR, "Studies in hypophosphatemic vitamin D-refractory osteomalacia in adults: oral phosphate supplement as an adjunctive therapy", Medicine (Baltimore), 44, pp.99~134 (1965)
- Haap M, "Association of serum phosphate levels with glucose tolerance, insuline sensitivity and insuline secretion in non-diabetic subjects", Eur J Clin Nutr, 60, pp.734~739 (2006)
- Ravenscroft AJ, "Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis", Anaesthesia, 54, pp.198~ (1999)
- Häqline, "Hypophosphataemia: cause of the disturbed metabolism in the metabolic syndrome", Med Hypotheses, 56, pp.657~663 (2001)